Kyverna Therapeutics (KYTX) News Today $1.86 +0.03 (+1.64%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.92 +0.06 (+3.44%) As of 04/17/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period JPMorgan Chase & Co. Trims Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)JPMorgan Chase & Co. lowered its position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,166,437 shares of the company's stock after sApril 17 at 3:15 AM | marketbeat.comKyverna Therapeutics (KYTX) vs. Its Rivals Head to Head ComparisonApril 17 at 2:02 AM | americanbankingnews.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Holdings Trimmed by Franklin Resources Inc.Franklin Resources Inc. cut its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 26.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 692,028 shares of the company's sApril 15 at 3:58 AM | marketbeat.comCritical Comparison: Kyverna Therapeutics (KYTX) vs. Its RivalsApril 14, 2025 | americanbankingnews.comHC Wainwright Has Negative Estimate for KYTX Q1 EarningsApril 8, 2025 | americanbankingnews.comEquities Analysts Offer Predictions for KYTX Q1 EarningsKyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Research analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for shares of Kyverna Therapeutics in a research report issued to clients and investors on Thursday, April 3rd. HC Wainwright analyst M. Kapoor now expectApril 8, 2025 | marketbeat.comHC Wainwright Lowers Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $4.00HC Wainwright decreased their price target on shares of Kyverna Therapeutics from $6.00 to $4.00 and set a "neutral" rating for the company in a research note on Thursday.April 5, 2025 | marketbeat.comKyverna Therapeutics price target lowered to $4 from $6 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comKyverna Therapeutics price target lowered to $20 from $40 at Morgan StanleyApril 2, 2025 | markets.businessinsider.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Buy" from AnalystsShares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have received a consensus recommendation of "Buy" from the six brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, four have assigned a buy reApril 2, 2025 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Given New $20.00 Price Target at Morgan StanleyMorgan Stanley decreased their target price on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating on the stock in a research report on Tuesday.April 2, 2025 | marketbeat.comKyverna Therapeutics price target lowered to $12 from $13 at UBSMarch 29, 2025 | markets.businessinsider.comKyverna Therapeutics sees cash and securities sufficient into 2027March 29, 2025 | markets.businessinsider.comKyverna Therapeutics files $250M mixed securities shelfMarch 29, 2025 | markets.businessinsider.comKyverna Therapeutics Advances CAR T-Cell Therapy TrialsMarch 29, 2025 | tipranks.comKyverna Therapeutics (NASDAQ:KYTX) Announces Earnings Results, Misses Expectations By $0.04 EPSKyverna Therapeutics (NASDAQ:KYTX - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.04).March 28, 2025 | marketbeat.comKyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 27, 2025 | prnewswire.comKyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025March 21, 2025 | seekingalpha.comKyverna Therapeutics (KYTX) Projected to Post Quarterly Earnings on TuesdayKyverna Therapeutics (NASDAQ:KYTX) will be releasing earnings before the market opens on Tuesday, March 25, Financial Modeling Prep reports.March 18, 2025 | marketbeat.comGRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF KYVERNA THERAPEUTICS, INC. (KYTX)March 14, 2025 | markets.businessinsider.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Buy" from AnalystsShares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have been assigned an average recommendation of "Buy" from the nine analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, seven have issued a buy ratingFebruary 13, 2025 | marketbeat.comKYTX stock touches 52-week low at $2.78 amid sharp annual declineFebruary 12, 2025 | msn.comFY2025 Earnings Estimate for KYTX Issued By Leerink PartnrsKyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for Kyverna Therapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($February 10, 2025 | marketbeat.comInvestors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTXFebruary 7, 2025 | globenewswire.comKYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities LawsuitFebruary 7, 2025 | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna TherapeuticsFebruary 7, 2025 | prnewswire.comAnalysts Issue Forecasts for KYTX FY2029 EarningsKyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Stock analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for Kyverna Therapeutics in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of (February 7, 2025 | marketbeat.comKyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTXFebruary 7, 2025 | prnewswire.comInvestors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTXFebruary 6, 2025 | globenewswire.comKYTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important February 7 Deadline in Securities Class Action – KYTXFebruary 6, 2025 | globenewswire.comThe Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTXFebruary 6, 2025 | prnewswire.comKyverna Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. February 7, 2025 Deadline to file Lead Plaintiff Motion.February 4, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTXFebruary 4, 2025 | prnewswire.comKyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitFebruary 4, 2025 | prnewswire.comINVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of February 7, 2025 Lead Plaintiff Deadline in the Kyverna Therapeutics, Inc. (KYTX) Securities Class Action – Investors With Significant Losses Encouraged to Contact the FirmFebruary 4, 2025 | globenewswire.comKYTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important February 7 Deadline in Securities Class Action - KYTXFebruary 4, 2025 | investing.comKYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law FirmFebruary 4, 2025 | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTXFebruary 4, 2025 | prnewswire.comFinal Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTXFebruary 4, 2025 | prnewswire.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna TherapeuticsFebruary 3, 2025 | markets.businessinsider.comKYTX FINAL DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important February 7 Deadline in Securities Class Action – KYTXFebruary 3, 2025 | globenewswire.comKYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitFebruary 3, 2025 | globenewswire.comShareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class Action – Contact The Gross Law Firm to Learn MoreFebruary 3, 2025 | globenewswire.comThe Gross Law Firm Notifies Kyverna Therapeutics, Inc. ...February 3, 2025 | gurufocus.comThe Gross Law Firm Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTXFebruary 3, 2025 | prnewswire.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 13.9% in JanuaryKyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 2,950,000 shares, a growth of 13.9% from the December 31st total of 2,590,000 shares. Currently, 15.8% of the company's stock are short sold. Based on an average daily volume of 335,500 shares, the short-interest ratio is presently 8.8 days.February 3, 2025 | marketbeat.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna TherapeuticsFebruary 2, 2025 | globenewswire.comKYTX FINAL DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important February 7 Deadline in Securities Class Action - KYFebruary 2, 2025 | investing.comKYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities LawsuitFebruary 1, 2025 | gurufocus.comKYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities LawsuitFebruary 1, 2025 | prnewswire.com Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address KYTX Media Mentions By Week KYTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYTX News Sentiment▼0.470.49▲Average Medical News Sentiment KYTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYTX Articles This Week▼47▲KYTX Articles Average Week Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORIC News STOK News TRML News ETON News ALLO News TRDA News AMLX News ALT News HRTX News RGNX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYTX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KYTX Stock Free KYTX Stock Alerts